Edwards Lifesciences has invested $35 million for an exclusive right to acquire Corvia Medical, which is engaged in a U.S. pivotal trial for its InterAtrial Shunt Device (IASD) to treat heart failure.
The IASD provides continuous decompression of the left atrium, which may reduce symptoms and slow the progression of heart failure, according to Edwards. It is also the first transcatheter device designed to treat heart failure with preserved or midrange ejection fraction, the companies stated.
"We are extremely pleased to have the support of the global leader in patient-focused innovations for structural heart disease as we continue to advance this novel treatment for heart failure," George Fazio, president and CEO of Corvia Medical, said in a press release. "We are proud of our accomplishments to date and look forward to completing the pivotal study with the support of our global clinical investigators."